ddd65fce-1a39-415c-9114-7a9c8e9b266c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.650
- MYC_TARGETS_V2+0.580
- OXIDATIVE_PHOSPHORYLATION+0.550
- E2F_TARGETS+0.540
- DNA_REPAIR+0.520
- INTERFERON_ALPHA_RESPONSE+0.520
- G2M_CHECKPOINT+0.410
- MTORC1_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- ALLOGRAFT_REJECTION+0.380
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- UV_RESPONSE_DN-0.400
- ANGIOGENESIS-0.300
- MYOGENESIS-0.300
- KRAS_SIGNALING_DN-0.220
- APICAL_JUNCTION-0.200
- WNT_BETA_CATENIN_SIGNALING-0.190
- APICAL_SURFACE-0.140
- COAGULATION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR17866821 | — | — | 0.915 |
| 2 | 46E565A7-5022-4648-9035-B60FC7CFD6E7 | — | — | 0.894 |
| 3 | cdef9a7f-9daa-4a33-b196-08a12a2ed203 | — | — | 0.891 |
| 4 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.889 |
| 5 | SRR11296765 | — | — | 0.883 |
| 6 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.882 |
| 7 | TCGA-A8-A06X-01A-21R-A00Z-07 | — | B | 0.882 |
| 8 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.876 |
| 9 | ERR2278852 | — | — | 0.867 |
| 10 | SRR2016960 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.520 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |